

Drug resistance interpretation: PR

PI Major Mutations:

PI Accessory Mutations:

PR Other Mutations:

None

None

L10V99%
seen=6,757 • T12I100%
seen=9,344 • I13V100%
seen=9,344 • G16E100%
seen=11,879 • E35D100%
seen=11,831 • M36I100%
seen=11,832 • R41K100%
seen=11,834 • R57K99%
seen=19,177 • I62V100%
seen=17,289 • L63N99%
seen=17,289 • I64V100%
seen=17,289 • H69Q99%
seen=17,718

Protease Inhibitors

atazanavir/r (ATV/r)

Susceptible

darunavir/r (DRV/r)

Susceptible

fosamprenavir/r (FPV/r)

Susceptible

indinavir/r (IDV/r)

Susceptible

lopinavir/r (LPV/r)

Susceptible

nelfinavir (NFV)

Susceptible

saquinavir/r (SQV/r)

Susceptible

tipranavir/r (TPV/r)

Susceptible

PR comments

Other

- L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations.

Mutation scoring: PR

HIVDB 9.5.1 (2023-11-05)

No drug resistance mutations were found for PI.

Drug resistance interpretation: RT

HIVDB 9.5.1 (2023-11-05)

NRTI Mutations:

NNRTI Mutations:

RT Other Mutations:

S68G100%
seen=5,117 • M184V100%
seen=17,289

K103N99%
seen=2,386

V35T100%
seen=11,780 • K49R100%
seen=11,116 • V60I100%
seen=7,287 • D121H99%
seen=1,868 • K122E100%
seen=1,861 • I135T100%
seen=7,714 • T139K99%
seen=7,685 • Q145M100%
seen=8,142 • P170PF99-100%
seen=19,621 • D177E100%
seen=11,017 • I178M100%
seen=16,107 • T200A100%
seen=19,189 • R211K99%
seen=17,992 • V245T100%
seen=1,144 • D250E99%
seen=2,879

Nucleoside Reverse Transcriptase Inhibitors

Non-nucleoside Reverse Transcriptase Inhibitors

abacavir (ABC)

Low-Level Resistance

zidovudine (AZT)

Susceptible

stavudine (D4T)

Susceptible

didanosine (DDI)

Potential Low-Level Resistance

emtricitabine (FTC)

High-Level Resistance

lamivudine (3TC)

High-Level Resistance

tenofovir (TDF)

Susceptible

doravirine (DOR)

Susceptible

efavirenz (EFV)

High-Level Resistance

etravirine (ETR)

Susceptible

nevirapine (NVP)

High-Level Resistance

rilpivirine (RPV)

Susceptible

RT comments

NRTI

- S68G is a polymorphic mutation that is often selected in combination with K65R. It partially restores the replication defect associated with K65R.
- M184V/I cause high-level in vitro resistance to 3TC and FTC and low/intermediate resistance to ABC (3-fold reduced susceptibility). M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT and TDF and are associated with clinically significant reductions in HIV-1 replication.

NNRTI

- K103N is a non-polymorphic mutation that confers high-level reductions in NVP and EFV susceptibility. It is the most commonly transmitted DRM.

Mutation scoring: RT

HIVDB 9.5.1 (2023-11-05)

Drug resistance mutation scores of NRTI:

Download CSV

Rule	ABC ⚡	AZT ⚡	D4T ⚡	DDI ⚡	FTC ⚡	3TC ⚡	TDF ⚡
M184V	15	-10	-10	10	60	60	-10

Drug resistance mutation scores of NNRTI:

Download CSV

Rule	DOR ⚡	EFV ⚡	ETR ⚡	NVP ⚡	RPV ⚡
K103N	0	60	0	60	0